Immune effects of α and β radionuclides in metastatic prostate cancer.
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
accepted:
23
07
2024
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
External beam radiotherapy is used for radical treatment of organ-confined prostate cancer and to treat lesions in metastatic disease whereas molecular radiotherapy with labelled prostate-specific membrane antigen ligands and radium-223 (
Identifiants
pubmed: 39192074
doi: 10.1038/s41585-024-00924-5
pii: 10.1038/s41585-024-00924-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
James, N. D. et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403, 1683–1722 (2024).
pubmed: 38583453
doi: 10.1016/S0140-6736(24)00651-2
Hague, C. & Logue, J. P. Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases. Ther. Adv. Urol. 8, 175–180 (2016).
pubmed: 27247627
pmcid: 4872188
doi: 10.1177/1756287216629870
McBean, R., O’Kane, B., Parsons, R. & Wong, D. Lu277-PSMA therapy for men with advanced prostate cancer: initial 18 months experience at a single Australian tertiary institution. J. Med. Imaging Radiat. Oncol. 63, 538–545 (2019).
pubmed: 31021525
doi: 10.1111/1754-9485.12891
Fong, L. et al. A phase 1b study of atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 27, 4746–4756 (2021).
pubmed: 34108181
pmcid: 8974420
doi: 10.1158/1078-0432.CCR-21-0063
Wang, S., Tang, W., Luo, H., Jin, F. & Wang, Y. The role of image-guided radiotherapy in prostate cancer: a systematic review and meta-analysis. Clin. Transl. Radiat. Oncol. 38, 81–89 (2023).
pubmed: 36407489
Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353–2366 (2018).
pubmed: 30355464
pmcid: 6269599
doi: 10.1016/S0140-6736(18)32486-3
Desouky, O., Ding, N. & Zhou, G. Targeted and non-targeted effects of ionizing radiation. J. Radiat. Res. Appl. Sci. 8, 247–254 (2019).
Parker, C. et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1119–1134 (2020).
pubmed: 32593798
doi: 10.1016/j.annonc.2020.06.011
Bolla, M., Henry, A., Mason, M. & Wiegel, T. The role of radiotherapy in localised and locally advanced prostate cancer. Asian J. Urol. 6, 153–161 (2019).
pubmed: 31061801
pmcid: 6488693
doi: 10.1016/j.ajur.2019.02.001
Mendez, L. C. & Morton, G. C. High dose-rate brachytherapy in the treatment of prostate cancer. Transl. Androl. Urol. 7, 357–370 (2018).
pubmed: 30050796
pmcid: 6043748
doi: 10.21037/tau.2017.12.08
Zaorsky, N. G. et al. The evolution of brachytherapy for prostate cancer. Nat. Rev. Urol. 14, 415–439 (2017).
pubmed: 28664931
pmcid: 7542347
doi: 10.1038/nrurol.2017.76
Goyal, J. & Antonarakis, E. S. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett. 323, 135–146 (2012).
pubmed: 22521546
pmcid: 4124611
doi: 10.1016/j.canlet.2012.04.001
Ritawidya, R. et al. Lutetium-177-labeled prostate-specific membrane antigen-617 for molecular imaging and targeted radioligand therapy of prostate cancer. Adv. Pharm. Bull. 13, 701–711 (2023).
pubmed: 38022814
pmcid: 10676551
doi: 10.34172/apb.2023.079
Marques, I. A. et al. Targeted alpha therapy using Radium-223: from physics to biological effects. Cancer Treat. Rev. 68, 47–54 (2018).
pubmed: 29859504
doi: 10.1016/j.ctrv.2018.05.011
Parker, C. et al. Alpha emitter radium 223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).
pubmed: 23863050
doi: 10.1056/NEJMoa1213755
Badrising, S. K. et al. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with radium-223. Prostate Cancer Prostatic Dis. 25, 248–255 (2022).
pubmed: 34446849
doi: 10.1038/s41391-021-00412-6
Morris, M. J. et al. Radium-224 mechanism of action: implications for use in treatment combinations. Nat. Rev. Urol. 16, 745–756 (2019).
pubmed: 31712765
pmcid: 7515774
doi: 10.1038/s41585-019-0251-x
O’Sullivan, J. M. et al. Results of the ADRRAD trial of pelvic IMRT plus radium-223 in men with mHSPC metastatic to bone. J. Clin. Oncol. 38, 136 (2020).
doi: 10.1200/JCO.2020.38.6_suppl.136
Turner, P. et al. First survival data from the ADRRAD clinical trial; pelvic radiotherapy and concurrent radium-223 in metastatic hormone sensitive prostate cancer (mHSPC). Clin. Oncol. 32, E130–E131 (2020).
doi: 10.1016/j.clon.2020.01.011
Sartor, O. et al. Lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).
pubmed: 34161051
pmcid: 8446332
doi: 10.1056/NEJMoa2107322
Emmett, L. et al. Lutetium177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J. Med. Radiat. Sci. 64, 52–60 (2017).
pubmed: 28303694
pmcid: 5355374
doi: 10.1002/jmrs.227
Rinne, S. S. & Vorobyeva, A. Radiometals — chemistry and radiolabeling. Nucl. Med. Mol. Imaging https://doi.org/10.1016/B978-0-12-822960-6.00044-2 (2022).
Jang, A., Kendi, A. T., Johnson, G. B., Halfdanarson, T. R. & Sartor, O. Targeted alpha-particle therapy: a review of current trials. Int. J. Mol. Sci. 24, 11626 (2023).
pubmed: 37511386
pmcid: 10380274
doi: 10.3390/ijms241411626
Brandmaier, A. & Formenti, S. The impact of radiation therapy on innate and adaptive tumor immunity. Semin. Radiat. Oncol. 30, 139–144 (2019).
doi: 10.1016/j.semradonc.2019.12.005
Wei, R., Liu, S., Zhang, S., Min, L. & Zhu, S. Cellular and extracellular components in tumor microenvironment and their application in early diagnosis of cancers. Anal. Cell. Pathol. 2020, 6283796 (2020).
doi: 10.1155/2020/6283796
Pun, J. et al. Identification of cancer-associated fibroblasts subtypes in prostate cancer. Front. Immunol. 14, 1133160 (2023).
pubmed: 37033924
pmcid: 10080037
doi: 10.3389/fimmu.2023.1133160
Hirz, T. et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat. Commun. 14, 663 (2023).
pubmed: 36750562
pmcid: 9905093
doi: 10.1038/s41467-023-36325-2
Wu, Z. et al. The landscape of immune cells infiltrating in prostate cancer. Front. Oncol. 10, 517637 (2020).
pubmed: 33194581
pmcid: 7658630
doi: 10.3389/fonc.2020.517637
Brown, J. M. Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. Br. J. Radiol. 87, 1035 (2013).
Eckert, F. et al. Impact of curative radiotherapy on the immune status of patients with localised prostate cancer. Oncoimmunology 7, e1496881 (2018).
pubmed: 30393582
pmcid: 6208674
doi: 10.1080/2162402X.2018.1496881
Hoffman, E. et al. Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localised prostate cancer. Cancer Immunol. Immunother. 71, 541–552 (2022).
doi: 10.1007/s00262-021-03002-6
Hurwitz, M. D. et al. Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer. Radiother. Oncol. 95, 350–358 (2010).
pubmed: 20430459
pmcid: 2883632
doi: 10.1016/j.radonc.2010.03.024
Finkelstein, S. E. et al. Combining immunotherapy and radiation for prostate cancer. Clin. Genitourin. Cancer 13, 1–9 (2015).
pubmed: 25450032
doi: 10.1016/j.clgc.2014.09.001
Kubo, M. et al. Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy. Oncol. Rep. 39, 417–424 (2018).
pubmed: 29138841
Philippou, Y. et al. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. Br. J. Cancer 123, 1089–1100 (2020).
pubmed: 32641865
pmcid: 7525450
doi: 10.1038/s41416-020-0956-x
Nesslinger, N. J. et al. Standard treatments induce antigen specific immune responses in prostate cancer. Clin. Cancer Res. 13, 1493–1502 (2007).
pubmed: 17332294
doi: 10.1158/1078-0432.CCR-06-1772
Schaue, D. et al. T-cell responses to surviving in cancer patients undergoing radiation therapy. Clin. Cancer Res. 14, 4883–4890 (2008).
pubmed: 18676762
pmcid: 2748652
doi: 10.1158/1078-0432.CCR-07-4462
Tuomela, K. et al. Radiotherapy transiently reduces the sensitivity of cancer cells to lymphocyte cytotoxicity. Proc. Natl Acad. Sci. USA 119, 3 (2022).
doi: 10.1073/pnas.2111900119
Wang, H. et al. Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: an exploratory study. Radiother. Oncol. 155, 80–85 (2021).
pubmed: 33172830
doi: 10.1016/j.radonc.2020.10.029
Xu, J. et al. CSFIR signalling blockade stanches tumour-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73, 2782–2794 (2013).
pubmed: 23418320
pmcid: 4097014
doi: 10.1158/0008-5472.CAN-12-3981
Ren, X. et al. Immunological classification of tumour types and advances in precision combination immunotherapy. Front. Immunol. 13, 790113 (2022).
pubmed: 35296094
pmcid: 8918549
doi: 10.3389/fimmu.2022.790113
Bonaventura, P. et al. Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol. 10, 168 (2019).
pubmed: 30800125
pmcid: 6376112
doi: 10.3389/fimmu.2019.00168
Stultz, J. & Fong, L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 24, 697–717 (2021).
pubmed: 33820953
pmcid: 8384622
doi: 10.1038/s41391-021-00340-5
Zhang, J., Huang, D., Saw, P. E. & Song, E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 43, 523–545 (2022).
pubmed: 35624021
doi: 10.1016/j.it.2022.04.010
Keam, S. P. et al. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. J. Immunother. Cancer 8, e000792 (2020).
pubmed: 32581061
pmcid: 7319782
doi: 10.1136/jitc-2020-000792
Andersen, L. B. et al. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J. Pathol. 255, 155–165 (2021).
pubmed: 34255349
doi: 10.1002/path.5757
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer immunity cycle. Immunity 39, 1–10 (2013).
pubmed: 23890059
doi: 10.1016/j.immuni.2013.07.012
Apetoh, L. et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220, 47–59 (2007).
pubmed: 17979839
doi: 10.1111/j.1600-065X.2007.00573.x
Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007).
pubmed: 17704786
doi: 10.1038/nm1622
Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2007).
pubmed: 17187072
doi: 10.1038/nm1523
Dar, T. B., Henson, R. M. & Shiao, S. L. Targeting innate immunity to enhance the efficacy of radiation therapy. Front. Immunol. 9, 3077 (2018).
pubmed: 30692991
doi: 10.3389/fimmu.2018.03077
Sharma, P., Wagner, K., Wolchok, J. D. & Allison, J. P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11, 805–812 (2012).
doi: 10.1038/nrc3153
Ruckert, M., Flohr, A. S., Hecht, M. & Gaipl, U. S. Radiotherapy and the immune system: more than just immune suppression. Stem Cell 39, 1155–1165 (2021).
doi: 10.1002/stem.3391
Colton, M., Cheadle, E. J., Honeychurch, J. & llidge, T. M. Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiat. Oncol. 15, 254 (2020).
pubmed: 33148287
pmcid: 7640712
doi: 10.1186/s13014-020-01678-1
Sharma, R. A. et al. Clinical development of new drug-radiotherapy combinations. Nat. Rev. Clin. Oncol. 13, 627–642 (2016).
pubmed: 27245279
doi: 10.1038/nrclinonc.2016.79
Carvalho, A. H. & Villar, R. C. Radiotherapy and immune response: the systemic effects of a local treatment. Clinics 73, e557s (2018).
pubmed: 30540123
doi: 10.6061/clinics/2018/e557s
Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862–870 (2004).
pubmed: 14967443
doi: 10.1016/j.ijrobp.2003.09.012
Honeychurch, J. & llidge, T. M. The influence of radiation in the context of developing combination immunotherapies in cancer. Ther. Adv. Vaccines Immunother. 5, 115–122 (2017).
pubmed: 29998216
doi: 10.1177/2051013617750561
Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumours. Nat. Med. 15, 1170–1178 (2009).
pubmed: 19767732
doi: 10.1038/nm.2028
Obeid, M. et al. Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14, 1848–1850 (2007).
pubmed: 17657249
doi: 10.1038/sj.cdd.4402201
Gameiro, S. R. et al. Radiation-induced immunogenic modulation of tumour enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 5, 403–416 (2014).
pubmed: 24480782
doi: 10.18632/oncotarget.1719
Golden, E. B. et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3, e28518 (2014).
pubmed: 25071979
pmcid: 4106151
doi: 10.4161/onci.28518
Chakraborty, M. et al. Irradiation of tumour cells upregulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. 170, 6338–6347 (2003).
pubmed: 12794167
doi: 10.4049/jimmunol.170.12.6338
Chakraborty, M. et al. External beam radiation of tumors alters phenotype of tumour cells to render them susceptible to vaccine-mediated T cell killing. Cancer Res. 64, 4328–4337 (2004).
pubmed: 15205348
doi: 10.1158/0008-5472.CAN-04-0073
Garnett, C. T. et al. Sublethal irradiation of human tumour cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64, 7985–7994 (2004).
pubmed: 15520206
doi: 10.1158/0008-5472.CAN-04-1525
Ifeadi, V. & Garnett-Benson, C. Sub-lethal irradiation of human colorectal tumour cells imparts enhanced and sustained susceptibility to multiple death receptors signalling pathways. PLoS One 7, e31762 (2012).
pubmed: 22389673
pmcid: 3289623
doi: 10.1371/journal.pone.0031762
Reits, E. A. et al. Radiation modulates the peptide repertoire enhances MHC class I expression, and induces successful antitumour immunotherapy. J. Exp. Med. 203, 1259–1271 (2006).
pubmed: 16636135
pmcid: 3212727
doi: 10.1084/jem.20052494
Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumour immunity in immunogenic tumours. Immunity 41, 843–852 (2014).
pubmed: 25517616
pmcid: 5155593
doi: 10.1016/j.immuni.2014.10.019
Diamond, J. M. et al. Exosome shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs. Cancer Immunol. Res. 6, 910–920 (2018).
pubmed: 29907693
pmcid: 6072562
doi: 10.1158/2326-6066.CIR-17-0581
Najafi, M. et al. Macrophage polarity in cancer: a review. J. Cell. Biochem. 120, 2756–2765 (2019).
pubmed: 30270458
doi: 10.1002/jcb.27646
Shevtsov, M., Sato, H., Multhoff, G. & Shibata, A. Novel approaches to improve the efficacy of immune-radiotherapy. Front. Oncol. 9, 156 (2019).
pubmed: 30941308
pmcid: 6433964
doi: 10.3389/fonc.2019.00156
Seifert, L. et al. Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice. Gastroenterology 150, 1659–1672 (2016).
pubmed: 26946344
doi: 10.1053/j.gastro.2016.02.070
Batlle, E. & Massague, J. Transforming growth factor-β signaling in immunity and cancer. Immunity 50, 924–940 (2019).
pubmed: 30995507
pmcid: 7507121
doi: 10.1016/j.immuni.2019.03.024
Ko, V. M. et al. Radiotherapy and cGAS/STING signaling: impact on MDSCs in the tumor microenvironment. Cell. Immunol. 362, 104298 (2021).
doi: 10.1016/j.cellimm.2021.104298
Liang, H. et al. Host STING-dependent MDSC mobilisation drives extrinsic radiation resistance. Nat. Commun. 8, 1736 (2017).
pubmed: 29170400
pmcid: 5701019
doi: 10.1038/s41467-017-01566-5
Eke, I. et al. Long-term expression changes of immune-related genes in prostate cancer after radiotherapy. Cancer Immunol. Immunother. 71, 839–850 (2022).
pubmed: 34435232
doi: 10.1007/s00262-021-03036-w
Derer, A. et al. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. Front. Immunol. 7, 610 (2016).
pubmed: 28066420
pmcid: 5177615
doi: 10.3389/fimmu.2016.00610
Wan, X. et al. The mechanism of low-dose radiation-induced upregulation of immune checkpoint molecule expression in lung cancer. Biochem. Biophys. Res. Commun. 607, 102–107 (2022).
doi: 10.1016/j.bbrc.2022.03.158
Ding, X. C. et al. The change of soluble programmed cell death-ligand 1 in glioma patients receiving radiotherapy and its impact on clinical outcome. Front. Immunol. 11, 580335 (2020).
pubmed: 33224142
pmcid: 7668030
doi: 10.3389/fimmu.2020.580335
Lin, Y., Xu, J. & Lan, H. Tumour-associated macrophages in tumour metastasis: biological roles and clinical therapeutic applications. J. Hematol. Oncol. 12, 76 (2019).
pubmed: 31300030
pmcid: 6626377
doi: 10.1186/s13045-019-0760-3
Haughey, C. M. et al. Investigating radiotherapy response in a novel syngeneic model of prostate cancer. Cancers 12, 2804 (2020).
pubmed: 33003551
pmcid: 7599844
doi: 10.3390/cancers12102804
Dovedi, S. J. et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin. Cancer Res. 23, 5514–5526 (2017).
pubmed: 28533222
doi: 10.1158/1078-0432.CCR-16-1673
Chen, R., Kang, R. & Tang, D. The mechanism of HMGB1 secretion and release. Exp. Mol. Med. 54, 91–102 (2022).
pubmed: 35217834
pmcid: 8894452
doi: 10.1038/s12276-022-00736-w
Kwak, M. S. et al. Peroxiredoxin-mediated disulfide bond formation is required for nucleocytoplasmic translocation and secretion of HMGB1 in response to inflammatory stimuli. Redox Biol. 24, 1012023 (2019).
doi: 10.1016/j.redox.2019.101203
De Groot, A. E. et al. Characterisation of tumour-associated macrophages in prostate cancer transgenic mouse model. Prostate 81, 629–647 (2021).
pubmed: 33949714
pmcid: 8720375
doi: 10.1002/pros.24139
Boibesset, C. et al. Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clin. Transl. Med. 12, e581 (2022).
doi: 10.1002/ctm2.581
Viola, A., Munari, F., Sánchez-Rodríguez, R., Scolaro, T. & Castegna, A. The metabolic signature of macrophage responses. Front. Immunol. 10, 1462 (2019).
pubmed: 31333642
pmcid: 6618143
doi: 10.3389/fimmu.2019.01462
Jubel, J. M., Barbati, Z. R., Burger, C., Dieter, C., Wirtz, D. C. & Schildberg, F. A. The role of PD-1 in acute and chronic infection. Front. Immunol. 11, 487 (2020).
pubmed: 32265932
pmcid: 7105608
doi: 10.3389/fimmu.2020.00487
Li, K. et al. PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. Nat. Commun. 12, 2746 (2021).
pubmed: 33980853
pmcid: 8115078
doi: 10.1038/s41467-021-22965-9
Wartewig, T. et al. PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. Nat. Cancer 4, 1508–1525 (2023).
pubmed: 37723306
pmcid: 10597841
doi: 10.1038/s43018-023-00635-7
Mizuno, R. et al. PD-1 primarily targets TCR signal in the inhibition of functional T-cell activation. Front. Immunol. 10, 630 (2019).
pubmed: 31001256
pmcid: 6455061
doi: 10.3389/fimmu.2019.00630
Kim, Y., Lavoie, R. R., Dong, H., Park, S. & Lucien-Matteoni, F. Radiotherapy inhibits the antitumour immune response through release of immunosuppressive tumor-derived extracellular vesicles in prostate cancer. Cancer Res. 81, abstract 675 (2021).
doi: 10.1158/1538-7445.AM2021-675
Cursano, M. C. et al. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: a review. Crit. Rev. Oncol. Hematol. 146, 102864 (2020).
pubmed: 31986318
doi: 10.1016/j.critrevonc.2020.102864
Malamas, A. S., Gameiro, S. R., Knudson, K. M. & Hodge, J. W. Sublethal exposure to alpha radiation (
pubmed: 27893426
pmcid: 5341329
doi: 10.18632/oncotarget.13520
Leung, C. N., Howell, D. M. & Howell, R. W. Radium-223 dichloride causes transient changes in natural killer cell population and cytotoxic function. Int. J. Radiat. Biol. 97, 1417–1424 (2021).
pubmed: 34264175
pmcid: 8580662
doi: 10.1080/09553002.2021.1956002
Kim, J. W. et al. Immune analysis of radium-223 in patients with metastatic prostate cancer. Clin. Genitourin. Cancer 16, e469–e476 (2018).
pubmed: 29137877
doi: 10.1016/j.clgc.2017.10.010
Kim, J. W. et al. Survival and immune analysis of radium-223 in patients with metastatic prostate cancer. Am. Soc. Clin. Oncol. 36, e24144 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.e24144
Vardaki, I. et al. Radium-223 treatment increase immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment. Clin. Cancer Res. 27, 3253–3264 (2021).
pubmed: 33753455
pmcid: 8172463
doi: 10.1158/1078-0432.CCR-20-4790
Aggarwal, R. R. et al. Immunogenic priming with
doi: 10.1200/JCO.2021.39.15_suppl.5053
Marshall, C. F. et al. Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer. Clin. Cancer Res. 27, 1623–1630 (2021).
pubmed: 33451978
pmcid: 8121020
doi: 10.1158/1078-0432.CCR-20-4476
Creemers, J. H. A. et al. Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer. Front. Oncol. 18, 667658 (2021).
doi: 10.3389/fonc.2021.667658
Handke, A. et al. Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy. J. Immunother. Cancer 11, e007354 (2023).
pubmed: 37857524
pmcid: 10603337
doi: 10.1136/jitc-2023-007354
Risbridger, G. P. et al. Preclinical models of prostate cancer: patient-derived xenografts, organoids and other explant models. Cold Spring Hard. Perspect. Med. 35, 485–489 (2018).
Dorff, T. B. et al. Evaluating changes in immune function and bone microenvironment during radium-223 treatment of patients with castration-resistant prostate cancer. Cancer Biother. Radiopharm. 35, 485–489 (2020).
pubmed: 32366119
Kgatle, M. M. et al. Immune checkpoints, inhibitors and radionuclides in prostate cancer: promising combinatorial therapy approach. Int. J. Mol. Sci. 22, 4109 (2021).
pubmed: 33921181
pmcid: 8071559
doi: 10.3390/ijms22084109